Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 45 articles: HTML format

Single Articles

April 2024
1. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
   Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
   PubMed     Abstract available
   
   
   March 2024
2. RAMANARAYANAN V, Oberdoerffer P
   AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
   Cancer Res. 2024;84:793-795.
   PubMed     Abstract available
   
   
   January 2024
3. HUANG TT, Chiang CY, Nair JR, Wilson KM, et al
   AKT1 interacts with DHX9 to mitigate R-loop-induced replication stress in ovarian cancer.
   Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1908.
   PubMed     Abstract available
   
   
   December 2023
4. HEO J, Kim YN, Shin S, Lee K, et al
   Serial circulating-tumor DNA analysis with a tumor naive next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer.
   Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429.
   PubMed     Abstract available
   
   
   October 2023
5. BEDDOWS I, Fan H, Heinze K, Johnson BK, et al
   Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes.
   Cancer Res. 2023 Oct 24. doi: 10.1158/0008-5472.CAN-23-1362.
   PubMed     Abstract available
   
   
   
6. ITO I, Yousef AMG, Chowdhury S, Dickson PN, et al
   Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
   Cancer Res. 2023;83:3184-3191.
   PubMed     Abstract available
   
   
   September 2023
7. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
   Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
   Cancer Res. 2023;83:2889-2907.
   PubMed     Abstract available
   
   
   August 2023
8. YU ZC, Li T, Tully E, Huang P, et al
   Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
   Cancer Res. 2023;83:2750-2762.
   PubMed     Abstract available
   
   
   
9. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
   Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
   Cancer Res. 2023;83:2557-2571.
   PubMed     Abstract available
   
   
   July 2023
10. WANG Y, Chen SY, Ta M, Senz J, et al
    Bi-allelic Dicer1 mutations in the gynecologic tract of mice drive lineage-specific development of DICER1 syndrome-associated cancer.
    Cancer Res. 2023 Jul 26:CAN-22-3620. doi: 10.1158/0008-5472.CAN-22-3620.
    PubMed     Abstract available
    
    
    June 2023
11. LI QS, Zheng PS
    ESRRB inhibits the TGF-beta signaling pathway to drive cell proliferation in cervical cancer.
    Cancer Res. 2023 Jun 23:CAN-23-0067. doi: 10.1158/0008-5472.CAN-23-0067.
    PubMed     Abstract available
    
    
    
12. ROSSI NM, Dai J, Xie Y, Wangsa D, et al
    Extrachromosomal Amplification of Human Papillomavirus Episomes Is a Mechanism of Cervical Carcinogenesis.
    Cancer Res. 2023;83:1768-1781.
    PubMed     Abstract available
    
    
    May 2023
13. CAO K, Zhang G, Yang M, Wang Y, et al
    Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer.
    Cancer Res. 2023 May 12:CAN-22-3260. doi: 10.1158/0008-5472.CAN-22-3260.
    PubMed     Abstract available
    
    
    
14. KELLIHER L, Lengyel E
    Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
    Cancer Res. 2023;83:1383-1385.
    PubMed     Abstract available
    
    
    
15. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    PubMed     Abstract available
    
    
    April 2023
16. LIU Y, Gusev A, Kraft P
    Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Cancer Res. 2023;83:1191-1202.
    PubMed     Abstract available
    
    
    February 2023
17. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    PubMed     Abstract available
    
    
    
18. FERRI-BORGOGNO S, Zhu Y, Sheng J, Burks JK, et al
    Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.
    Cancer Res. 2023 Feb 14:CAN-22-1821. doi: 10.1158/0008-5472.CAN-22-1821.
    PubMed     Abstract available
    
    
    January 2023
19. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    PubMed     Abstract available
    
    
    December 2022
20. JUNGLES KM, Green MD
    Fat Fuels the Fire in Cervical Cancer.
    Cancer Res. 2022;82:4513-4514.
    PubMed     Abstract available
    
    
    
21. HAWKINS SM, Nephew KP
    Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Cancer Res. 2022;82:4511-4512.
    PubMed     Abstract available
    
    
    
22. ALSINA-SANCHIS E, Mulfarth R, Moll I, Bohn S, et al
    Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages.
    Cancer Res. 2022;82:4414-4428.
    PubMed     Abstract available
    
    
    November 2022
23. WANG CK, Chen TJ, Tan GYT, Chang FP, et al
    MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis.
    Cancer Res. 2022 Nov 10. pii: 710535. doi: 10.1158/0008-5472.CAN-22-1159.
    PubMed     Abstract available
    
    
    October 2022
24. ATIYA HI, Frisbie L, Goldfeld E, Orellana T, et al
    Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation.
    Cancer Res. 2022 Oct 11. pii: 709712. doi: 10.1158/0008-5472.CAN-22-1294.
    PubMed     Abstract available
    
    
    
25. MUHAMMAD N, Ruiz F, Stanley J, Rashmi R, et al
    Mono- and diunsaturated fatty acids sensitize cervical cancer to radiation therapy.
    Cancer Res. 2022 Oct 10. pii: 709678. doi: 10.1158/0008-5472.CAN-21-4369.
    PubMed     Abstract available
    
    
    
26. CHAMBERS LM, Esakov Rhoades EL, Bharti R, Braley C, et al
    Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.
    Cancer Res. 2022 Oct 7. pii: 709668. doi: 10.1158/0008-5472.CAN-22-0455.
    PubMed     Abstract available
    
    
    
27. WANG Y, Huang P, Wang BG, Murdock T, et al
    Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis.
    Cancer Res. 2022 Oct 7. pii: 709669. doi: 10.1158/0008-5472.CAN-22-1620.
    PubMed     Abstract available
    
    
    
28. HO GY, Kyran EL, Bedo J, Wakefield MJ, et al
    Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin.
    Cancer Res. 2022 Oct 7. pii: 709667. doi: 10.1158/0008-5472.CAN-21-4012.
    PubMed     Abstract available
    
    
    
29. LU X, Xin DE, Du JK, Zou QC, et al
    Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression.
    Cancer Res. 2022 Oct 5. pii: 709611. doi: 10.1158/0008-5472.CAN-22-0848.
    PubMed     Abstract available
    
    
    September 2022
30. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    PubMed     Abstract available
    
    
    August 2022
31. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    PubMed     Abstract available
    
    
    July 2022
32. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    PubMed     Abstract available
    
    
    April 2022
33. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available
    
    
    March 2022
34. OSORIO JC, Zamarin D
    Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.
    Cancer Res. 2022;82:766-768.
    PubMed     Abstract available
    
    
    
35. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    PubMed     Abstract available
    
    
    February 2022
36. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    PGC1alpha/beta EXPRESSION PREDICTS THERAPEUTIC RESPONSE TO OXIDATIVE PHOSPHORYLATION INHIBITION IN OVARIAN CANCER.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    PubMed     Abstract available
    
    
    December 2021
37. MANDAL G, Biswas S, Anadon CM, Yu X, et al
    IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer.
    Cancer Res. 2021 Dec 23. pii: 0008-5472.CAN-21-2376.
    PubMed     Abstract available
    
    
    
38. O'CONNOR CM, Taylor SE, Miller KM, Hurst L, et al
    Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-1987.
    PubMed     Abstract available
    
    
    November 2021
39. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    PubMed     Abstract available
    
    
    
40. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    PubMed     Abstract available
    
    
    October 2021
41. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    PubMed     Abstract available
    
    
    September 2021
42. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    PubMed     Abstract available
    
    
    
43. HENKLE TR, Lam B, Kung YJ, Lin J, et al
    Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
    Cancer Res. 2021;81:4560-4569.
    PubMed     Abstract available
    
    
    June 2021
44. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    PubMed     Abstract available
    
    
    May 2021
45. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.